NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-HD-19-020 from the NIH Guide for Grants and Contracts
Notice NOT-AR-19-040 from the NIH Guide for Grants and Contracts
Notice NOT-HD-19-019 from the NIH Guide for Grants and Contracts
Notice NOT-MH-19-049 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-142 from the NIH Guide for Grants and Contracts
Notice NOT-DC-19-007 from the NIH Guide for Grants and Contracts
Notice NOT-MH-19-050 from the NIH Guide for Grants and Contracts
Notice NOT-MH-19-038 from the NIH Guide for Grants and Contracts
Notice NOT-AR-19-041 from the NIH Guide for Grants and Contracts
Notice NOT-DK-19-015 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-20-024 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from clinical investigators to participate in the National Drug Abuse Treatment Clinical Trials Network (CTN) and contribute to the network's capacity to respond to urgent public health needs. NIDA intends to continue to develop and test interventions for addressing the wide spectrum of substance use problems via collaborative partnerships among NIDA, clinical research investigators, healthcare providers, and healthcare institutions.
Notice NOT-MH-19-047 from the NIH Guide for Grants and Contracts
Notice NOT-MH-19-046 from the NIH Guide for Grants and Contracts
Notice NOT-AG-19-037 from the NIH Guide for Grants and Contracts
Notice NOT-MH-19-045 from the NIH Guide for Grants and Contracts
Notice NOT-HD-19-024 from the NIH Guide for Grants and Contracts
Notice NOT-PM-19-004 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HL-20-021 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support high risk/high reward research on the blood/vascular component and regulation of the neurovascular-blood unit (a.k.a., Blood-Brain Barrier; BBB) in normal and pathological states to create enhanced/modified platforms that more closely model the human BBB. Research addressing vascular, hemostatic, hematopoietic, and/or immune cell interaction across the Blood-Brain Interface is of particular interest. This initiative will serve to stimulate the development of a new field of science and re-define the neurovascular unit to also include the blood/vascular component to develop the next generation of pre-clinical human cellular model systems of the human BBB to complement research currently based on animal models.
Funding Opportunity PAR-19-362 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for a planning grant from institutions in low- and middle-income countries (LMICs) to 1.) Design a Global Infectious Disease (GID) Research Training Program in collaboration with U.S. collaborators and 2.) Strengthen LMIC faculty and prepare advanced courses and training resources for the program envisioned at the LMIC institution. The application should propose a collaborative process to create a new training program that will strengthen the capacity of the LMIC institution to conduct infectious disease research. Applications should include activities to strengthen LMIC faculty leadership and skills as well as prepare advanced scientific didactic and methodology courses and research training resources development relevant to the program to be planned. A detailed vision for a research training program that focuses on a major endemic or life-threatening emerging infectious disease, neglected tropical disease, infections that frequently occur as a co-infection in HIV infected individuals or infections associated with non-communicable disease conditions of public health importance in LMICs should be proposed.
Funding Opportunity PAR-19-357 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical, and preclinical and/non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis.